A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 769 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR ‘Hamilton’ Star Who Battled Breast Cancer is Giving Back to Current... May 19, 2021 Patient Guide in Prostate Cancer Now Available in Vietnamese December 10, 2025 Can Using a Microwave Cause Cancer? March 25, 2021 What People With Cancer and Survivors Should Know About Vaping: An... September 26, 2023 Load more HOT NEWS Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival The UK Government’s response to Javed Khan’s tobacco review: A small... Blood Test May Help Identify Which Colorectal Cancer Patients with Liver... The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer...
